Enanta Pharmaceuticals, Inc. (ENTA)
12.27
-0.23
(-1.84%)
USD |
NASDAQ |
Oct 12, 12:01
Enanta Pharmaceuticals Profit Margin (Quarterly) : -135.8% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -135.8% |
| March 31, 2026 | -76.29% |
| December 31, 2025 | -64.13% |
| September 30, 2025 | -123.6% |
| June 30, 2025 | -99.68% |
| March 31, 2025 | -151.7% |
| December 31, 2024 | -131.4% |
| September 30, 2024 | -197.3% |
| June 30, 2024 | -126.1% |
| March 31, 2024 | -182.7% |
| December 31, 2023 | -185.6% |
| September 30, 2023 | -148.5% |
| June 30, 2023 | -206.8% |
| March 31, 2023 | -211.6% |
| December 31, 2022 | -122.9% |
| September 30, 2022 | -129.7% |
| June 30, 2022 | -162.7% |
| March 31, 2022 | -179.5% |
| December 31, 2021 | -108.9% |
| September 30, 2021 | -104.3% |
| June 30, 2021 | -111.1% |
| March 31, 2021 | -109.5% |
| December 31, 2020 | -26.24% |
| September 30, 2020 | -124.2% |
| June 30, 2020 | -76.48% |
| Date | Value |
|---|---|
| March 31, 2020 | -21.74% |
| December 31, 2019 | 25.57% |
| September 30, 2019 | 17.91% |
| June 30, 2019 | 15.86% |
| March 31, 2019 | 10.46% |
| December 31, 2018 | 37.22% |
| September 30, 2018 | 40.80% |
| June 30, 2018 | 35.43% |
| March 31, 2018 | 28.50% |
| December 31, 2017 | 30.68% |
| September 30, 2017 | 48.08% |
| June 30, 2017 | -112.2% |
| March 31, 2017 | -60.19% |
| December 31, 2016 | -47.81% |
| September 30, 2016 | -14.03% |
| June 30, 2016 | -7.70% |
| March 31, 2016 | -12.65% |
| December 31, 2015 | 54.06% |
| September 30, 2015 | 40.32% |
| June 30, 2015 | 20.85% |
| March 31, 2015 | 50.12% |
| December 31, 2014 | 54.21% |
| September 30, 2014 | -191.2% |
| June 30, 2014 | |
| March 31, 2014 | -240.9% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | -33.31K% |
| Coherus Oncology, Inc. | -233.1% |
| BridgeBio Pharma, Inc. | -63.97% |
| RenovoRx, Inc. | -320.2% |
| ACADIA Pharmaceuticals, Inc. | 10.23% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -64.75% |
| Return on Assets | -20.60% |
| Return on Invested Capital | -21.68% |
| Gross Profit Margin (Quarterly) | 91.75% |
| Operating Margin (Quarterly) | -120.0% |
| Return on Net Operating Assets | -80.14% |